Gene therapy of chronic granulomatous disease |
| |
Authors: | Grez M Becker S Saulnier S Knöss H Ott M G Maurer A Dinauer M C Hoelzer D Seger R Hossle J P |
| |
Affiliation: | Laboratory for Molecular Virology, Georg-Speyer-Haus, Frankfurt, Germany. |
| |
Abstract: | Chronic granulomatous disease (CGD) is a primary immunodeficiency disorder which results from absence or malfunction of the respiratory burst oxidase normally expressed in neutrophils and other phagocytic leukocytes. Two-thirds of the patients are males hemizygous for mutations in the X-linked gene coding for gp91-phox. As a therapeutic approach towards the X-linked form of CGD bicistronic retroviral vectors containing the gp91-phox gene and a selectable marker gene were constructed. The ability of these vectors to restore NADPH oxidase activity was tested in a human myeloid leukemic cell line that is defective in superoxide production, as well as in primary CD34+ cells obtained from X-CGD patients. Under optimal conditions 80% of the CD34+ cells derived from bone marrow of one X-CGD patient were transduced. The level of superoxide production, in phagocytes derived from transduced cells was 68.9% of normal levels. Considering that low levels of superoxide generating activity are sufficient for normal host defense, the present experiments provide the basis for the development of a gene replacement therapy for the X-linked form of CGD. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|